DUBLIN--(BUSINESS WIRE)--The "The 8th Annual Brain Injury Conference - Industry" conference has been added to ResearchAndMarkets.com's offering.
This conference brings together researchers and clinicians from industry, academia, the military and government to present ground-breaking research in a variety of areas related to traumatic brain injury.
This event provides a special opportunity for a variety of stakeholders to present original research and analysis aimed at providing a full picture of the progress being made towards better diagnosis, treatment and long-term care for TBI survivors.
At this annual event, physicians, nurses, neurosurgeons, scientists, and drug/diagnostic developers from all over the world network and learn from one another.
Focus areas include:
- Current Clinical Management of TBI
- Advances and Opportunities for TBI Biomarkers
- Recovery, Regeneration and Plasticity
- TBI Therapeutic Preclinical/Clinical Candidates
- Outcomes Research
- Large-scale Observational Studies of TBI
- Neuroimaging Research and Practice
- Emerging Tools for Diagnosis/Assessment of TBIs
- Preclinical/Clinical Development Models/Design
About Traumatic Brain Injury
Traumatic Brain Injury (TBI) is a major cause of death and disability globally and is considered a serious public health problem. In the US, an estimated 1.7 million people sustain a TBI every year, and over 30 percent of all reported injury-related deaths list TBI as a contributing factor. Moreover, mild traumatic brain injury is the most common combat-related injury and along with spinal cord injury, TBI accounts for nearly 25 percent of combat casualties.
Treatment of TBI and especially acute TBI is still a major unmet medical need. Therapies that prove an ability to limit the damage done to the brain and improve clinical outcomes of patients of TBI will have a major impact on the global pharmaceutical market.
Although past clinical trials for new therapies have ended in failure, there is indeed renewed interest in this field and with recent initiatives from both the US Congress and Department of Defense to improve treatment options for TBI patients, the time has come for a rethinking of the potential for pharmaceutical management of this condition.
For more information about this conference visit https://www.researchandmarkets.com/research/tzx6xn/the_8th_annual?w=4